FDA Puts IkT-148009 Parkinson’s Clinical Trial on Hold
The U.S. Food and Drug Administration (FDA) has put a hold on clinical trials of IkT-148009, an experimental oral therapy…
Articles by Marisa Wexler, MS
NeuroOne Plans to Ask FDA to Clear RF Ablation System in New Year
NeuroOne Medical Technologies announced it has successfully completed a feasibility study of its OneRF ablation system, which uses implanted…
NE3107 Plus Levodopa Leads to Better Motor Gains: Phase 2 Trial
BioVie’s investigational oral therapy NE3107, taken in combination with standard levodopa, eases motor symptoms more substantially than levodopa alone…
‘Widespread Imbalance’ Seen in Gut Microbiome of Parkinson’s Patients
More than 30% of gut microbial species are found at abnormal numbers in Parkinson’s disease patients, according to a new…
Home Health Visits Plus Peer Mentors May Ease Caregiver Strain
Pairing at-home healthcare visits with peer mentoring may help to prevent the strain of caregiving from worsening over time among…
New Vaccine for Parkinson’s Moves Closer to 1st Human Trials
An experimental vaccine that stimulates immune responses against three regions of the alpha-synuclein protein — whose toxic clumps contribute to…
Using AI to Analyze Gait May Help Diagnose Parkinson’s Disease
New machine learning models based on walking patterns accurately distinguished between Parkinson’s patients and healthy people, and between different…
Predicting Whose Parkinson’s Will Progress to Speed Therapy Trials
A machine-learning tool that combines genetic and clinical data can distinguish, with a high level of accuracy, between fast- and…
Repetitive Genetic Variations Tied to Parkinson’s Risk in Study
Variations in small, repetitive DNA sequences called short tandem repeats (STRs) are associated with an altered risk of developing…
Elements in ‘Dark Genome’ Tied to Disease Progression Differences
Transposable elements, a common feature in the so-called “dark genome,” are associated with clinical differences in how Parkinson’s disease…